Urology

Results showed that bpMRI was noninferior to mpMRI for detecting clinically significant prostate cancer, defined as Gleason Grade Group 2 or higher.

By aligning pretreatment risk stratification more closely with AS eligibility, clinicians may feel more confident recommending surveillance, potentially reducing overtreatment.

This study investigated the microbiota of the distal ileum in patients undergoing iRARC without bowel preparation, using direct sampling during ICUD.

Overall, this research offers a practical web-based prediction tool that can support clinicians in tailoring patient follow-up and treatment.

Integrating routine hormone testing with pelvic floor ultrasound assessments could help identify high-risk women early.

The model was subsequently applied to 11,723 examinations in men who had no documented diagnosis of prostate cancer at the time of MRI, with an average patient age of 65.5 years.

With limited early-detection tools and only modest improvements in survival for advanced disease, clinicians urgently need reliable biomarkers to improve prognostication.

Discover a study showing lasting survival gains from treatment intensification in prostate cancer.